Erythromycin 13C D3
| Product Name | Erythromycin 13C D3 |
|---|---|
| Alternate Names | Erythromycin Stable Isotopes, Stable Isotopes of Erythromycin |
| CAT No. | CS-O-06591 |
| CAS No. | 959119-26-7 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 737.94 g/mol |
| Mol. For. | C₃₆¹³CH₆₄D₃NO₁₃ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Erythromycin |
| Purity | 95% |
| Therapeutic | Antihistamine |
| Smileys | C[C@@H]([C@@H]([C@H](C(O[C@@H]1CC)=O)C)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@](O)(C[C@H](C([C@@H]([C@@H](O)[C@@]1(O)C)C)=O)C)C)O[C@@](O[C@H](C)C[C@@H]3N(C)[13C]([2H])([2H])[2H])([H])[C@@H]3O |
| Canonical Smiles | CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O |
| InchIKey | ULGZDMOVFRHVEP-ZFHWVPMOSA-N |
| Inchl | InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19?,20+,21+,22-,23?,24?,25-,26?,28?,29+,30-,31?,32-,34?,35-,36?,37-/m1/s1/i11+1D3 |
| IUPAC | (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-6-[3-hydroxy-6-methyl-4-[methyl(trideuterio(113C)methyl)amino]oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Erythromycin 13C D3 is a stable isotope-labelled derivative of Erythromycin, which is a macrolide antibiotic commonly used to treat bacterial infections. The compound is labeled with stable isotopes of Carbon-13, which allows for the compound to be easily traced and quantified in biological systems.
Erythromycin 13C D3 works by inhibiting the growth of bacteria, primarily by interfering with the bacterial ribosome's ability to synthesize proteins. This leads to the death of the bacterial cell and the eventual eradication of the infection. The compound is effective against a wide range of bacterial strains, including Streptococcus, Staphylococcus, and Haemophilus influenzae.
The stable isotope labeling of Erythromycin 13C D3 allows for more precise analysis of the compound's pharmacokinetics and pharmacodynamics in the body. It can be used in clinical trials to determine the optimal dosage and administration frequency of Erythromycin, as well as to study the compound's metabolism and distribution in the body.
In summary, Erythromycin 13C D3 is a stable isotope-labeled derivative of Erythromycin that is effective against a range of bacterial infections. Its stable isotopic labeling allows for precise analysis of its pharmacokinetics and pharmacodynamics, making it a useful tool in clinical trials and research studies.
Get an Instant Quote
Related Compounds
Erythromycin Ethyl Succinate D6 | Erythromycin Ethylsuccinate-13C-D3 | Erythromycin D6 | Erythromycin D3 | N-Demethyl Erythromycin A D3 | Nitroso-N-De methyl Erythromycin-D3 | Erythromycin Ethylsuccinate-D5 |